Table 1.
Baseline characteristics of the modified intention-to-treat cohort
| Palonosetron arm | Granisetron arm | |
|---|---|---|
| (n = 555) | (n = 559) | |
| Gender, n (%) | ||
| Female | 326 (58.7) | 324 (58.0) |
| Male | 229 (41.3) | 235 (42.0) |
| Age, years | ||
| Mean (SD) | 58.4 (10.4) | 58.0 (10.5) |
| ≥55 years, n (%) | 376 (67.7) | 380 (68.0) |
| <55 years, n (%) | 179 (32.3) | 179 (32.0) |
| Tumor type, n (%) | ||
| Non-small cell lung cancer | 248 (44.7) | 249 (44.5) |
| Small cell lung cancer | 47 (8.5) | 52 (9.3) |
| Breast cancer | 239 (43.1) | 236 (42.2) |
| Others | 21 (3.8) | 22 (3.9) |
| Chemotherapy, n (%) | ||
| Cisplatin | 316 (56.9) | 323 (57.8) |
| AC/EC | 239 (43.1) | 236 (42.2) |
| Previous chemotherapy, n (%) | ||
| Naive | 519 (93.5) | 516 (92.3) |
| Non-naive | 36 (6.5) | 43 (7.7) |
AC/EC doxorubicin or epirubicin with cyclophosphamide, SD standard deviation